We are developing a new class of therapeutics derived from sRNA-signatures

PIPELINE OF THERAPEUTIC PROGRAMS FOCUS ON AREAS WITH KNOWN HETEROGENEITY

Inflammation

Fibrosis

Neurodegeneration

ESTABLISHED ECOSYSTEM OF BIOTECH COMPANIES, RESEARCH ORGANIZATIONS, FOUNDATIONS AND ACADEMIC INSTITUTIONS

Academic collaborators

Drug developers

Technology providers

"Gatehouse Bio has taken a unique approach to deciphering roles for the entire spectrum of non-coding small RNAs. By invoking unbiased analytic methods, GHB has identified novel diagnostic and functionally significant disease related effects. "

— Director, Genome Science Institute

"Gatehouse’s technology and machine learning generated algorithms have the potential to be Transformational for drug R&D. Their approach is disruptive in the pharmaceutical arena and will expedite precision medicine to patients in great need of disease-modifying therapeutics."

— Director of translational neuroscience

"The role of small RNAs in regulating gene expression is understood; GHB’s innovative approach and robust methodology provide insights into genes and pathways that drive disease. The outcome of this pivotal work can help define the next step towards precision medicine and novel targets. "

— Senior Director Emerging Innovations Unit

Want to learn more?

We have established a global network of collaborators across academia, industry and patient advocacy groups, who share our vision and commitment to patients.